Clinical trial sites often open and close rapidly, with 60% ceasing operations within the first year, impacting patient access. The high closure rate of trial sites reflects unique research objectives ...
AUSTIN, Texas, Nov. 19, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results